Visioneering Technologies, Inc.

Equities

VTI

AU000000VTI2

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
0.145 AUD -17.14% Intraday chart for Visioneering Technologies, Inc. -12.12% -42.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study MT
Visioneering Technologies Issues Part of Shortfall from Rights Offering MT
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
Transcript : Visioneering Technologies, Inc., Q3 2023 Earnings Call, Oct 18, 2023
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion MT
Visioneering Technologies Appoints CEO MT
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023 CI
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023 CI
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Visioneering Technologies, Inc., Q2 2023 Earnings Call, Jul 21, 2023
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
Transcript : Visioneering Technologies, Inc., Q1 2023 Earnings Call, Apr 20, 2023
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal MT
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Visioneering Technologies, Inc. Announces Board Changes CI
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial MT
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT CI
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Transcript : Visioneering Technologies, Inc., Q2 2022 Earnings Call, Jul 20, 2022
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial MT
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control CI
Visioneering Technologies, Inc. Announces Board Changes CI
Chart Visioneering Technologies, Inc.
More charts
Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. VTI Stock
  4. News Visioneering Technologies, Inc.
  5. Visioneering Technologies : Upsizes Security Purchase Plan to $890,000